You have 9 free searches left this month | for more free features.

Lymphoma, B-Cell

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital,Fudan University
Jul 10, 2023

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Shanghai, Shanhai, China
      Ruijin Hospital
    Sep 29, 2023

    SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • +2 more
      • (no location specified)
      Jun 22, 2023

      DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • Mitoxantrone Hydrochloride Liposome Injection
      • Jinan, Shandong, China
        Affiliated Cancer Hospital of Shandong First Medical University
      May 16, 2023

      Frontline of ASCT in High-risk DLBCL

      Recruiting
      • Diffuse Large B Cell Lymphoma
        • Beijing, Beijing, China
          Peking University People's Hospital
        Apr 26, 2023

        Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

        Recruiting
        • Relapsed or Refractory B-cell Lymphoma
        • infusion of JY231 injection
        • Guangzhou, Guangdong, China
          Guangdong Second Provincial General Hospital
        Sep 17, 2023

        Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

        Not yet recruiting
        • Relapsed/Refractory Large B-cell Lymphoma
        • (no location specified)
        Oct 6, 2023

        Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

        Not yet recruiting
        • Lymphoma, B-Cell
        • CD19 and CD22 targeted CAR-T cells
        • Langfang, Hebei, China
          Hebei Yanda Ludaopei Hospital
        Dec 6, 2022

        CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

        Recruiting
        • CD20-positive B-cell Non-Hodgkin's Lymphoma
        • Beijing, China
          Cancer Hospital Chinese Academy of Medical Sciences
        Apr 6, 2023

        Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

        Recruiting
        • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
        • dualCAR-NK19/70 cell
        • Shanghai, Shanghai, China
          Shanghai Tongji Hospital, Tongji University School of Medicine
        Apr 24, 2023

        DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

        Not yet recruiting
        • Diffuse Large B-Cell Lymphoma
        • High-grade B-cell Lymphoma
        • Loncastuximab Tesirine
        • (no location specified)
        Dec 13, 2022

        B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)

        Not yet recruiting
        • B-cell Lymphoma
        • CAR20(NAP)-T
        • +2 more
        • Stockholm, Sweden
        • +1 more
        Aug 15, 2023

        DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

        Recruiting
        • DLBCL - Diffuse Large B Cell Lymphoma
        • Follicular Lymphoma
        • Lenalidomide combined with G-CHOP (LO CHOP)
        • Xiamen, Fujian, China
          Bing Xu
        Nov 28, 2023

        Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

        Recruiting
        • Relapsed or Refractory B-cell Lymphoma
        • +6 more
        • Beijing, China
          Beijing Cancer Hospital
        Feb 6, 2023

        Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

        Completed
        • Diffuse Large B-cell Lymphoma
          • East Hanover, New Jersey
            Novartis
          Jun 16, 2023

          Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

          Not yet recruiting
          • Relapsed Non-Hodgkin Lymphoma
          • +6 more
          • (no location specified)
          Apr 12, 2023

          Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

          Not yet recruiting
          • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
          • +5 more
          • Boston, Massachusetts
          • +1 more
          Jun 28, 2023

          Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

          Available
          • Large B-cell Lymphoma
          • +4 more
          • Epcoritamab
          • (no location specified)
          Feb 16, 2023

          Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

          Not yet recruiting
          • Diffuse Large B-cell Lymphoma
          • (no location specified)
          Mar 23, 2023

          Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

          Not yet recruiting
          • Cancer
          • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
          • Fludarabine (30 mg/m^2)
          • +2 more
          • (no location specified)
          Jul 25, 2023

          Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

          Recruiting
          • Follicular Lymphoma
          • +4 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Jan 20, 2023